Clinical trial
Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With…
NCT00148135 · University of Michigan Rogel Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00148135 |
|---|---|
| Title | Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site |
| Official title | A Phase II Trial Evaluating the Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma of Unknown Primary |
| Intervention type | Drug |
| Interventions | Carboplatin, Gemcitabine, Capecitabine |
| Start date | May 1, 2001 |
| Primary completion | Apr 1, 2006 |
| Completion | Oct 1, 2007 |
| First posted | Sep 7, 2005 |
| Last update posted | Jan 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: